CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2003-10-28): Roche's Pegasys shown advantageous for treatment of hepatitis B

Drug & Device Development

Roche's Pegasys shown advantageous for treatment of hepatitis B

Last Updated: 2003-10-28 16:39:36 -0400 (Reuters Health)

ZURICH (Reuters) - Roche Holding AG unveiled on Tuesday results of a clinical trial that showed its Pegasys interferon to be superior to standard therapy for the hardest-to-treat form of hepatitis B.

The phase III trial presented at a U.S. medical congress showed Pegasys was more effective than lamivudine in treating patients with "variant" hepatitis B and that adding lamivudine to Pegasys did not make it work any better.

The 537-patient trial found 42.9% of those treated with Pegasys alone saw the amount of virus in their bloodstreams fall to the desired level, while only 29.3% of those on lamivudine did.

Roche said it would seek regulatory approval for Pegasys in hepatitis B treatment next year.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.